Annovis Bio opened lower at $0.85, compared with its previous close of $0.85. In the last trading session, the stock traded between $0.82 and $0.90. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Annovis Bio is now worth
$ 2.60
Resulting in a loss of
$ 97.40 (97.40%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.01 (-0.86%)
Day High
$0.90
Day Low
$0.82
Day Open
$0.85
Prev Close
$0.85
Volume
10,99,838
1W Return
-29.21%
1M Return
-26.43%
3M Return
-55.12%
6M Return
-64.60%
1Y Return
-59.91%
Fundamentals
Market Cap ($ Mn)
36
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-176.59%
ROCE
-176.27%
EPS (TTM)
$-0.35
Investment Returns
1 Week
-29.21%
1 Month
-26.43%
3 Months
-55.12%
6 Months
-64.60%
9 Months
-64.30%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
14Aug
Annovis Bio Q2 EPS of $(0.40) beats $(0.45) estimate
Annovis Bio reported Q2 2026 EPS of $(0.40), beating the $(0.45) estimate, while widening its net loss to $14.8 million due to a 131% surge in R&D expenses. The company achieved full enrollment of 850 patients in its pivotal Phase 3 Alzheimer’s trial. Despite stable cash holdings of $18.7 million, stockholders’ equity turned negative to $(4.3 million) due to a sharp rise in warrant liabilities.
3mo ago
8Jul
Roth Capital initiates coverage on Annovis Bio with Buy rating
Roth Capital analyst Boobalan Pachaiyappan has initiated coverage on Annovis Bio with a Buy rating and a price target of $8. The rating reflects a positive outlook for the company's stock.
4mo ago
7Jul
Annovis Bio completes enrollment of 850 patients in Phase 3 Alzheimer's trial
Annovis Bio, Inc. completed enrollment of 850 patients in its Phase 3 trial of buntanetap for early Alzheimer's disease across 83 US sites. The trial features a dual design with symptomatic data readout expected in Q1 2027 and disease-modifying data in Q1 2028. The company is preparing for NDA submissions to the FDA following these milestones.
